• Sign in

  • Join for free
  • Donate Today!
  • We are Social
    • Facebook
    • Twitter
    • Instagram
    • YouTube
    • LinkedIn
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
Secondary1st
  • Donate Today!

Search

Login

Register
  • 020 8905 3955info@secondary1st.org.uk
0
Secondary1st
  • Menu
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Volunteer
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News & Media
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
  • Donate Today!
20November

NICE approves two new drugs

Next
Previous
November 20, 2017
By cuco_admin_sec
0 Comment

NICE (The National Institute For Health and Care Excellence) has announced that two new breast cancer drugs, palbociclib (Ibrance) and ribociclib (Kisqali), are to be made available to NHS patients in England. These have been licensed as first-line treatments for post-menopausal patients with HR positive and HER2 negative locally advanced or metastatic breast cancer and work well when given with the aromatase inhibitor letrozole. Palbociclib and ribociclib are part of a new class of drugs that work by inhibiting the action of two cell division proteins, CDK 4 and CDK6. More research into the action of other proteins on cell division and spread is being carried out.

Categories: News
  • Search

  • Sign up for Newsletter

    * = required field
  • Categories

    • Event
    • Fundraising
    • In the media
    • News
    • Past Events
    • Rosie's blog
    • Uncategorised
    • Your Stories
  • Latest News

    • Carol goes Ziplining at Eighty

      May 09, 2022

    • Lucy, Lara, Anoushka, Alexander, Theo, Elica and Emily Go Cycling

      May 09, 2022

    • All-Day Fundraiser

      May 09, 2022

    • Lyndell Does It Again

      May 09, 2022

  • Who We Are

    • Who we are
    • Our Story
    • Rosie
    • Rosie’s blog
    • Our Trustees
    • Our Patrons
  • What We Do

    • What we do
  • Secondary Breast Cancer

    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Where to go for information
  • Get Involved

    • How to fundraise
    • Our Fundraisers

© 2016 - 2022 Secondary First is a Company Limited by Guarantee. Registered in England and Wales No. 9920657. Registered Office: 1st Floor Healthaid House, Marlborough Hill, Harrow, HA1 1UD. It is a Registered Charity Number 1165614.
Site maintained by CuCo Creative.

  • Cookie Policy
  • Privacy Policy